Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q3 2016 · 10-Q
Revenue$1.20M$1.20M+3.4% vs Q3 2015 Net Income-$1.20M-$1.20MN/M vs Q3 2015 EPS Diluted-$0.02-$0.02N/M vs Q3 2015 Gross Profit$66,000+19.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flowderived-$756,000N/M Free Cash Flowderived-$981,000N/M Margins · derivedGross margin5.5%+0.7 pt vs Q3 2015
Operating margin-110.8%−20.0 pt vs Q3 2015
Net margin-99.7%−17.4 pt vs Q3 2015
ended Mar 31, 2016 · filed May 10, 2016 · 40 d after period end